PEAK6
CRSP icon

PEAK6’s CRISPR Therapeutics CRSP Stock Holding History

PEAK6’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.6M Sell
213,300
-82,600
-28% -$4.35M 0.02% 505
2026
Q1 		$14.1M Buy
295,900
+21,400
+8% +$1.13M 0.03% 460
2025
Q4 		$14.4M Sell
274,500
-96,600
-26% -$5.79M 0.03% 494
2025
Q3 		$24.1M Sell
371,100
-25,000
-6% -$1.44M 0.04% 363
2025
Q2 		$19.3M Sell
396,100
-81,900
-17% -$3.17M 0.04% 394
2025
Q1 		$16.3M Buy
478,000
+464,400
+3,415% +$19.7M 0.04% 404
2024
Q4 		$535K Buy
+13,600
New +$642K ﹤0.01% 2117

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

PEAK6's CRSP Position: Q2 2026 in Review

PEAK6 reduced its CRISPR Therapeutics (CRSP) stake by 79% in Q2 2026, selling an estimated $4.55M and leaving 22,316 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #1594.

PEAK6 first reported a position in CRSP in Q1 2025 and has held it in 4 quarters since. The position peaked at $5.17M in Q1 2026. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • PEAK6 held 22,316 shares of CRISPR Therapeutics worth $1.22M as of Q2 2026.
  • PEAK6 sold 86,288 CRISPR Therapeutics shares in Q2 2026, an estimated $4.55M.
  • CRISPR Therapeutics made up ﹤0.01% of PEAK6's portfolio in Q2 2026, its #1594 holding.
  • PEAK6 first reported a position in CRISPR Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • PEAK6's CRISPR Therapeutics position peaked at $5.17M in Q1 2026.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on PEAK6's 13F filing for Q2 2026, filed 13 Aug 2026.